US 11,691,970 B2
Pyrazolopyridinone compounds
Haibing Guo, Shanghai (CN); Zhao-Kui Wan, Shanghai (CN); Luoheng Qin, Shanghai (CN); Qian Liu, Shanghai (CN); and Wing Shun Cheung, Shanghai (CN)
Assigned to Janssen Pharmaceutica NV, Beerse (BE)
Appl. No. 16/766,477
Filed by Janssen Pharmaceutica NV, Beerse (BE)
PCT Filed Nov. 23, 2018, PCT No. PCT/CN2018/117295
§ 371(c)(1), (2) Date May 22, 2020,
PCT Pub. No. WO2019/101182, PCT Pub. Date May 31, 2019.
Claims priority of application No. PCT/CN2017/112835 (WO), filed on Nov. 24, 2017.
Prior Publication US 2021/0147411 A1, May 20, 2021
This patent is subject to a terminal disclaimer.
Int. Cl. C07D 519/00 (2006.01); C07D 471/04 (2006.01); A61P 35/00 (2006.01)
CPC C07D 471/04 (2013.01) [C07D 519/00 (2013.01)] 45 Claims
 
1. A compound of formula (I):

OG Complex Work Unit Chemistry
or a tautomeric or stereochemically isomeric form thereof, wherein:
A1, A2 and A3 each independently are CH, CRa or N, provided that maximum two of A1, A2 and A3 are CRa;
C1 is hydrogen or C1-4alkyl;
C2 is hydrogen, C1-4alkyl, hydroxyl or C1-4alkoxy;
or C1 and C2 are taken together to form a C3-6cycloalkyl together with the carbon atom to which they are attached;
Y is a direct bond, —O—, C(═O), NRy, S(═O)2, or C1-4alkyl;
Ry is hydrogen or C1-4alkyl;
each Ra independently is C1-6alkyl, haloC1-6alkyl, halo, C1-6alkoxy, carboxyl, C1-6alkyl-oxycarbonyl, C2-6alkenyl, C2-6alkynyl, cyano, cyanoC1-6alkyl, hydroxyC1-6alkyl, —C(═O)—NH2, —C(═O)—NH(C1-4alkyl), —C(═O)—N(C1-4alkyl)2, or a 3 to 6 membered monocyclic saturated heterocyclyl containing at least one heteroatom that is N, O or S;
Rb is hydrogen, C1-6alkyl, haloC1-6alkyl, C1-6alkoxy, C1-6alkyloxycarbonyl, C2-6alkenyl, C2-6alkynyl, cyanoC1-6alkyl, hydroxyC1-6alkyl, —C(═O)—NH2, —C(═O)—NH(C1-4alkyl), —C(═O)—N(C1-4alkyl)2, C3-6cycloalkyl, phenyl, a 3 to 6 membered monocyclic heterocyclyl containing at least one heteroatom that is N, O or S, or C1-6alkyl substituted with C3-6cycloalkyl or with phenyl or with a 3 to 6 membered monocyclic heterocyclyl containing at least one heteroatom that is N, O or S;
D is a 3 to 12 membered heterocyclyl containing at least one heteroatom that is N, O or S, wherein said heterocyclyl is optionally substituted with 1 to 5 Rc substituents;
each Rc independently is oxo, halo, C1-6alkyl, C1-6alkyloxy, hydroxyC1-6alkyl, haloC1-6alkyl, haloC1-6alkyloxy, carboxyl, HOOC—C1-6alkyl-, C1-6alkyl substituted with —C(═O)—O—C1-6alkyl, C1-6alkyl-O—C(═O)—, cyano, cyanoC1-6alkyl, C1-6alkyl-C(═O)—, —SO2—C1-6alkyl, C3-6cycloalkyl, phenyl, a 3 to 6 membered monocyclic saturated heterocyclyl containing at least one heteroatom that is N, O or S, or a 5 or 6 membered monocyclic aromatic heterocyclyl containing at least one heteroatom that is N, O or S;
B is a 3 to 12 membered carbocyclyl or a 3 to 12 membered heterocyclyl containing at least one heteroatom that is N, O or S, wherein said carbocyclyl and heterocyclyl are each optionally substituted with 1 to 5 R substituents;
each R independently is C1-6alkyl, cyano, halo, C1-6alkoxy, haloC1-6alkoxy, hydroxyl, hydroxyC1-6alkyl, haloC1-6alkyl, oxo, —SO2—NH2, —SO2—NH(C1-4alkyl), —SO2—N(C1-4alkyl)2, —NH—C(═O)—C2-6alkenyl, —C(═O)—C1-6alkyl, —C(═O)—C2-6alkenyl, C1-6alkyl-O—C(═O)—, C3-6cycloalkyl, phenyl, or a 3 to 6 membered monocyclic heterocyclyl containing at least one heteroatom that is N, O or S;
or a pharmaceutically acceptable salt thereof or a solvate thereof.